Risk factors and outcome of COVID-19 in patients with hematological malignancies
| العنوان: | Risk factors and outcome of COVID-19 in patients with hematological malignancies |
|---|---|
| المؤلفون: | Carmen Eva Perez, Maria Trabazo, Diana Martínez, Irene Garcia-Garcia, Carola Diaz, Rocío Parody, Rosa Coll, José Luis Piñana, Rebeca Bailén, Ignacio De La Fuente, Marta Valero, María-José Jiménez, Irene García-Cadenas, Teresa Zudaire, I Espigado, Agustin Nieto, Ana Serrano, Angel Cedillo, Noemí Fernández, Guiomar Bautista, Adolfo Saez, María Dolores Morales, Luisa Sisinni, Beatriz Merchán, Lourdes Vázquez, Anna Sureda, Laura Fox, Josep-Maria Ribera, Rodrigo Martino, Alejandro Luna, Ana I. Pimentel, Juan Carlos Vallejo, Gonzalo Benzo, Jose Lopez, Carme Talarn, Raquel Saldaña, María Calbacho, Anabelle Chinea, Dunia de Miguel, Maria Carmen Montoya, Manuel Jurado, Irene Gómez-Catalan, Carlos Solano, Marta González-Vicent, Pascual Fernández |
| المساهمون: | Piñana, José Luis, Piñana, José Luis [0000-0001-8533-2562], Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH), [Piñana,JL] Hematology División, Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitaria La Fe, Valencia, Spain. [Piñana,JL] CIBERONC, Instituto Carlos III, Madrid, Spain. [Martino,R, Garcia‑Cadenas,I] Hematology División, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [García-García,I, Luna,A, Chinea,A, Saez,AJ] Hematology División, Hospital Ramon y Cajal, Madrid, Spain. [Parody,R, Sureda,A] Hematology División, Institut Català Oncologia-Hospital Duran i Reynals, Barcelona, Spain. [Morales,MD, Merchán,B, de Miguel,D] Hematology División, Hospital de Guadalajara, Guadalajara, Spain. [Benzo,G] Hematology División, Hospital La Princesa, Madrid, Spain. [Gómez-Catalan,I, Serrano,A, Montoya,MC] Hematology División, Hospital de Albacete, Albacete, Spain. [Coll,R] Hematology División, Institut Català Oncologia-Hospital Josep Trueta, Girona, Spain. [De La Fuente,I, Pérez,C] Hematology División, Hospital Clínico de Valladolid, Valladolid, Spain. [Diaz,C] Hematology División, Hospital Carlos Haya, Malaga, Spain. [Lopez, JL] Hematology División, Hospital Fundación Jiménez Díaz, Madrid, Spain. [Bailen,R] Hematology División, Hospital Gregorio Marañon, Madrid, Spain. [Zudaire,T] Hematology División, Hospital de Navarra, Navarra, Spain. [Martínez,D] Hematology División, Hospital a Coruña, Coruña, Spain. [Jurado,M] Hematology División, Hospital Virgen de la Nieves, Granada, Spain. [Calbacho,M] Hematology División, Hospital 12 de Octubre, Madrid, Spain. [Vázquez,L] Hematology División, Hospital Universitario de Salamanca, Salamanca, Spain. [Fox,L] Hematology División, Hospital Vall d`Hebron, Barcelona, Spain. [Pimentel,AI] Hematology División, Hospital Clínico Universitario Lozano Blesa, IIS Aragon, Zaragoza, Spain. [Bautista,G] Hematology División, Hospital Puerta de Hierro, Madrid, Spain. [Nieto,A] Hematology División, Hospital de Vigo, Vigo, Spain. [Fernandez,P] Hematology División, Hospital General de Alicante, Alicante, Spain. [Vallejo,JC] Hematology División, Hospital de Donostia, Donostia, Spain. [Solano,C] Hematology División, Hospital Clínico Universitario de Valencia, Valencia, Spain. [Valero,M] Hematology División, Hospital Arnau de Vilanova, Valencia, Spain.[Espigado,I] Department of Hematology, University Hospital Virgen del Rocío/ University of Sevilla, CSIC/ Institute of Biomedicine of Sevilla, Sevilla, Spain. [Saldaña,R] Hematology División, Hospital de Jerez, Jerez, Spain. [Sisinni,L] Pediatric Hematology-Oncology División, Hospital la Paz, Madrid, Spain. [Ribera,JM, Jimenez,MJ] Hematology División, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Badalona, Spain. [Trabazo,M] Pediatric División, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Gonzalez-Vicent,M] Pediatric División, Hospital niño Jesús, Madrid, Spain. [Fernández,N] Hematology División, Hospital Marqués de Valdecilla, Santander, Spain. [Talarn,C] Hematology División, Hospital Joan XXIII, Tarragona, Spain. [Cedillo,A] Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH), Madrid, Spain. [Piñana,JL] Division of Clinical Hematology, Hospital Universitario la Fe de Valencia, Valencia, Spain., Institut Català de la Salut, [Piñana JL] Hematology División, Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitaria La Fe, Valencia, Spain. CIBERONC, Instituto Carlos III, Madrid, Spain. Division of Clinical Hematology, Hospital Universitario la Fe de Valencia, Avda Fernando Abril Martorell, 106 CP 46026 Valencia, Spain. [Martino R] Hematology División, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [García-García I] Hematology División, Hospital Ramon y Cajal, Madrid, Spain. [Parody R] Hematology División, Institut Català Oncologia-Hospital Duran i Reynals, Barcelona, Spain. [Morales MD] Hematology División, Hospital de Guadalajara, Guadalajara, Spain. [Benzo G] Hematology División, Hospital La Princesa, Madrid, Spain. [Fox L] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Dipòsit Digital de la UB Universidad de Barcelona Digital.CSIC. Repositorio Institucional del CSIC instname Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Experimental Hematology & Oncology, Vol 9, Iss 1, Pp 1-16 (2020) Scientia Experimental Hematology & Oncology |
| بيانات النشر: | BioMed Central, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, Diseases::Neoplasms::Neoplasms by Site::Hematologic Neoplasms [Medical Subject Headings], COVID-19 (Malaltia) - Mortalitat, Coronavirus infections, Azithromycin, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Retrospective Studies [Medical Subject Headings], Reacción en cadena de la polimerasa, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Hematologic neoplasms, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Hematology, Factors de risc en les malalties, Stem cell transplantation, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Transplantation::Cell Transplantation::Stem Cell Transplantation::Hematopoietic Stem Cell Transplantation [Medical Subject Headings], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], lcsh:Diseases of the blood and blood-forming organs, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, Multicenter study, Polymerase chain reaction, Oncology, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Transplantation::Cell Transplantation::Stem Cell Transplantation [Medical Subject Headings], 030220 oncology & carcinogenesis, Malalties hematològiques, Factores de riesgo, medicine.drug, medicine.medical_specialty, Pronòstic mèdic, Risk factors in diseases, Infecciones por coronavirus, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Analysis of Variance::Multivariate Analysis [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::C-Reactive Protein [Medical Subject Headings], Neutropenia, Hematologia oncològica, lcsh:RC254-282, Trasplante de células madre, 03 medical and health sciences, Other subheadings::Other subheadings::Other subheadings::/mortality [Other subheadings], Internal medicine, medicine, Persons::Persons::Age Groups::Child [Medical Subject Headings], Mortality, neoplasias::neoplasias por localización::neoplasias hematológicas [ENFERMEDADES], Persons::Persons::Age Groups::Adult [Medical Subject Headings], Estudio multicéntrico, Estudio restrospectivo, Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], Otros calificadores::Otros calificadores::Otros calificadores::/mortalidad [Otros calificadores], Performance status, lcsh:RC633-647.5, business.industry, SARS-CoV-2, Research, Neoplasias hemtaológicas, Hematologic diseases, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality [Medical Subject Headings], COVID-19, Retrospective cohort study, Odds ratio, Neoplasms::Neoplasms by Site::Hematologic Neoplasms [DISEASES], medicine.disease, Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [Medical Subject Headings], Confidence interval, Retrospective studies, Transplantation, 030104 developmental biology, Sang - Malalties, Mortalidad, Risk factor, business |
| الوصف: | Background Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined. Patients and methods This was a Spanish transplant group and cell therapy (GETH) multicenter retrospective observational study, which included a large cohort of blood cancer patients with laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020. Results We included 367 pediatric and adult patients with hematological malignancies, including recipients of autologous (ASCT) (n = 58) or allogeneic stem cell transplantation (allo-SCT) (n = 65) from 41 hospitals in Spain. Median age of patients was 64 years (range 1–93.8). Recipients of ASCT and allo-SCT showed lower mortality rates (17% and 18%, respectively) compared to non-SCT patients (31%) (p = 0.02). Prognostic factors identified for day 45 overall mortality (OM) by logistic regression multivariate analysis included age > 70 years [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.2–3.8, p = 0.011]; uncontrolled hematological malignancy (OR 2.9, 95% CI 1.6–5.2, p 20 mg/dL (OR 3.3, 95% CI 1.7–6.4, p |
| وصف الملف: | application/pdf |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ed6d8fd73d4e915ad1a968cc4a2a7f4Test http://hdl.handle.net/2445/174432Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9ed6d8fd73d4e915ad1a968cc4a2a7f4 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |